Medtronic PLC received two pieces of good news about its HVAD ventricular assist device at the International Society for Heart and Lung Transplantation (ISHLT) Scientific Meeting in San Diego, with encouraging results reported from the LATERAL and ENDURANCE trials.
HVAD, which Medtronic acquired when it bought HeartWare for $1.1bn in August 2016, is approved in Europe as a bridge-to-transplant...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?